| Trial Name: |
CASE 1203
|
| Intro: |
Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma |
| Condition: |
|
| Description: |
This study will assess the total response rate of the Oxaliplatin, irinotecan and Capecitabine drug combination in advanced gastric/esophageal junction carcinoma. Patients will receive Oxaliplatin and Irinotecan weekly for 4 weeks plus Capecitabine twice a day for 4 weeks. Once cycle of treatment consists of 4 weeks of treatment followed by a 2-week rest. Patients will continue on treatment until disease progression or until unacceptable toxicity occurs. |
| Criteria: |
- Patients must have histologically or cytologically confirmed gastric adenocarcinoma or adenocarcinoma of the gastroesophageal junction. Patients must have metastatic or inoperable locally advanced disease
- Patients must not have received prior chemotherapy for metastatic or recurrent disease. One course of neoadjuvant chemotherapy and/or adjuvant chemotherapy with or without radiation therapy as primary treatment is acceptable
- At least 4 weeks must have elapsed since prior radiation therapy and patients must have been off previous anti-cancer therapy for at least 4 weeks
- Patients must not have a known hypersensitivity to 5-fluorouracil or history of allergic reactions attributed to compounds of similar chemical or biologic composition to Oxaliplatin, irinotecan and Capecitabine
- Patients must have adequate bone marrow, liver and kidney function.
|
| Contact: |
For Cancer Information, Current Clinical Trials, and Referral to a Physician please call (216) 844-5432 or (800) 641-2422 |
Participant Confidentiality:
All information regarding participation in Clinical Trials is treated with the
utmost confidentiality. University Hospitals Case Medical Center and the
Division of Clinical Research recognize and respect the confidentiality of this
information. Access to information related to clinical trials and their
participants is restricted to authorized clinical trials personnel only.
Back